Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPhA/NAPM merger

Executive Summary

Associations will not officially merge until April 1 because the National Association of Pharmaceutical Manufacturers has already collected dues for the first quarter. Four NAPM members who will join the Generic Pharmaceutical Association's board following completion of the merger have already participated in two board meetings. NAPM President Robert Milanese will become GPhA VP-programs & education (1"The Pink Sheet" Feb. 5, p. 26)

You may also be interested in...



NAPM/GhPA Merger Likely Ends Generic User Fees Push In 107th

The merger agreement between the National Association of Pharmaceutical Manufacturers and the Generic Pharmaceutical Association likely means that generic drug user fees will not be a focal point of the PDUFA reauthorization process.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

PS037392

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel